CSL welcomes the Patent Box Policy

New Patent Box policy will benefit domestic commercialisation of medical research

CSL welcomes domestic mRNA vaccine development

Onshore mRNA manufacturing will build Australian capability for next generation vaccine technologies

CSL Behring Announces Agreement with uniQure

Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B …

Update on COVID-19 Vaccine Numbers

2020 RAI Awardees Announced

Four Australian Research Programs to be Fast-Tracked in Partnership with CSL

CSL update on ATAGI advice for AZ COVID-19 Vaccine

CSL’s Global Role in Battling COVID-19

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19 …

COVID-19 Update

CSL continues to provide medicines to patients around the world.